1 Just The Facts Ma’am Dementia Care & Anti-Psychotics Just The Facts Ma’am December 17, 2012 Ronald A. Savrin, MD, MBA, FACS Medical Director, Ohio KePRO.

Slides:



Advertisements
Similar presentations
Living Better with Chemistry: Regulating with Drugs Joel Lexchin MD School of Health Policy and Management, York University Emergency Department, University.
Advertisements

Indianapolis Discovery Network for Dementia Comparative Effectiveness Research Trial of Alzheimers Disease Drug: COMET-AD.
Improving Dementia Care and Reducing Unnecessary Use of Antipsychotic Medications in Nursing Homes Alice Bonner, PhD, RN Division of Nursing Homes Center.
New England Journal of Medicine October 18;367: Relapse Risk after Discontinuation of Risperidone in Alzheimer’s disease Molly Moncrieff.
BACKGROUND: ANTIPSYCHOTIC TREATMENT OF YOUNG CHILDREN.
Powys-wide, Primary care audit Rhiannon Davies, Powys tHB Medicines Management Team Prescribing of Antipsychotic Medication in Patients with Dementia.
DUR Board Meeting March 12, 2008 West Virginia Department of Health and Human Resources Bureau for Medical Services Drug Utilization Review Board.
Arkansas Children’s Behavioral Health Care Commission AR DHS Division of Medical Services Pharmacy Program Laurence H. Miller, M.D., Senior Psychiatrist.
The Right Prescription A Call to Action for junior doctors on the use of antipsychotic drugs for people with dementia.
Reducing Unnecessary Antipsychotic Use in Dementia Residents: Prescriber/Medical Director Perspective Karl Steinberg, MD, CMD President, Stone Mountain.
University of DundeeSchool of Medicine Best practice in managing pneumonia: Scottish National Audit Project – Community Acquired Pneumonia (SNAP-CAP) Peter.
The Antipsychotic Atlas Project - Overview Kennedy, J (PI); S Murphy; S McPherson & M Layton (co-Is) Start date: 9/13End date: 8/15 This research project.
Omnibus Budget Reconciliation Act (OBRA-90) Goal To save money.
Criteria for Psychiatric Symptoms in Alzheimer’s Disease Clinical Trials Jeffrey L. Cummings, M.D. Alzheimer’s Disease Center UCLA School of Medicine FDA.
HOSPITAL BASED INPATIENT PSYCHIATRIC SERVICES (HBIPS) MEASURE SET Kathy Wonderly RN, BSPA, CPHQ Performance Improvement Coordinator Developed: February,
1 Tolvaptan for the Treatment of Hyponatremia Aliza Thompson, MD Medical Officer Cardiovascular and Renal Drugs Advisory Committee Meeting June 25, 2008.
UPDATE ON F329/309 AND DEMENTIA CARE Lisa Venditti, CEO Long Term Solutions Inc
Rajesh R. Tampi, MD, MS, FAPA
1 Lotronex ® (alosetron HCl) Tablets Risk-Benefit Issues Victor F. C. Raczkowski, M.D. Director, Division of Gastrointestinal and Coagulation Drug Products.
1 Reducing the Use of Antipsychotic Medications: First Steps on the Quality Improvement Journey December 17, 2012 Leasa Novak, LPN, BA.
An Update on NSAID Labeling and Data Review DSaRM Advisory Committee February 10, 2006 Sharon Hertz, M.D. Deputy Director Division of Anesthesia, Analgesia,
What FDA Failed to Disclose 1991, 2006 Vera Hassner Sharav Alliance for Human Research Protection.
Dementia Care Without Restraints: Think Critically and Change Practices Anthony Chicotel Staff Attorney California Advocates for Nursing Home Reform.
ANTIPSYCHOTIC DRUG USE IN SKILLED NURSING FACILITIES Rhonda Anderson, RHIA President AHIS, Inc.
Pharmacy Northern Region Update 2013 Doug Englebert, R.Ph August 28, 2013.
Antipsychotic Medications in the Primary Care Practice Angelo Potenciano, M.D.
Prior Authorization Criteria for PDL Classes: Alzheimer’s Anti-emetics High Potency Statins Hormone Replacement Therapy Multiple Sclerosis – Tysabri Charles.
Increase the Proportion of Metabolic Syndrome Screening In Adults with Severe Mental Illness receiving "atypical” second generation antipsychotics.
Regulation of Promotion of Prescription Drugs Thomas W. Abrams, R.Ph., MBA Division of Drug Marketing, Advertising, and Communications Food and Drug Administration.
Best Practice Guide: Treatment and care for behavioural and psychological symptoms Clive Ballard, Anne Corbett, Alistair Burns Alzheimer’s Society UK.
# 1: F 282 The services provided or arranged by the facility must be provided by qualified persons in accordance with each resident’s written plan of.
Placebo-Controls in Short-Term Clinical Trials of Hypertension Sana Al-Khatib, MD, MHS Assistant Professor of Medicine Division of Cardiology Duke University.
A-MOP: An Antipsychotic Medication Optimization Program for Long Term Care Fiona Sudbury, RN, Director of Care Duncan Robertson, Chief of Medical Staff.
Use of Atypical Antipsychotic Drugs by Children and Adolescents in the United States: A Retrospective Cohort Study Lesley H. Curtis, PhD Center for Clinical.
Using Recent Research to Improve the Cost-Effectiveness of VA Antipsychotic Formulary Policy Robert Rosenheck MD Michael Sernyak MD New England MIRECC.
WHAT IS THE EVIDENCE ON EFFECTIVENESS OF ANTIPSYCHOTICS IN PERSONS WITH DEMENTIA? 1.
Alan Breier, M.D. Leader, Zyprexa Product Team Lilly Research Fellow Professor of Psychiatry, Indiana University School of Medicine Adjunct Associate of.
Sertraline Use in Pediatric Population: A Risk Benefit Discussion Steven J. Romano, MD September 13, 2004 Steven J. Romano, MD September 13, 2004 Joint.
Use of Antipsychotic Drugs in Dementia Josepha A. Cheong, MD University of Florida Departments of Psychiatry and Neurology Chief, Division of Geriatric.
Issues to be addressed Is BPSD one entity? Is BPSD part of the diagnosis of dementia? Are BPSD symptoms which cut across diagnoses? Which syndromes have.
Evidence Based Advertising Part I Using the TMA as evidence in HCP advertising.
Monitoring for Inappropriate Use of Antipsychotic Medications F428 – Drug Regimen Review Process F329 – Unnecessary Medications Margie Huguet, RN, MCS.
Teresa Hudson, PharmD Center for Mental Healthcare and Outcomes Research South Central Mental Illness Research Education and Clinical Center.
Long-Term Efficacy Data for Psychiatric Drugs Thomas Laughren, M.D. Director, Division of Psychiatry Products (HFD-130) PDAC Meeting (Oct 25, 2005)
General Regulatory Issues in the Development of Drugs Intended for Treatment of Chronic Illness Sharon Hertz, M.D. Medical Officer Division of Anesthetic,
Prescribing in Dementia. Plan What to prescribe? When to prescribe? How to review? Who to review?
Drugs Used for Psychoses Chapter 18 Mosby items and derived items © 2010, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc.
Mental Health Nursing: Pharmacology: Antipsychotic Medications C. Calzolari 2016.
National Partnership to Improve Dementia Care 1 Denise F. O’Donnell, RN, MN, GCMS-BC, MASM, NHA Nurse Consultant/ Division of Nursing Homes/Survey and.
Carina Signori, DO Journal Club August 2010 Macdonald, M. et al. Diabetes Care; Jun 2010; 33,
NICE guidance Generalised Anxiety Disorder Alex Hill.
27 June 2000Victor F. C. Raczkowski, M.D.1 Risk-Management Options Victor F. C. Raczkowski, M.D., M.S. Gastrointestinal Drugs Advisory Committee 27 June.
News You Can Use… Phillip Transou, PharmD Candidate Pete Koval, PharmD Cone Health Family Medicine June, 2016.
Antipsychotic Medications: Prevalence of Inappropriate Use, Polypharmacy, and Non-Adherence Nancy G. Pham, PharmD; Lisa Le, MS; Karen M. Stockl, PharmD;
Management of Geriatric Psychiatric Disorders Arash Mirabzadeh Psychiatrist University of Social Welfare and Rehabilitation Sciences.
Clinical Trials for Comparative Effectiveness Research Mark Hlatky MD Mark Hlatky MD Stanford University January 10, 2012.
Date of download: 9/20/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Effects of a Palliative Care Intervention on Clinical.
The AHRQ Safety Program for Improving Antibiotic Use
WHAT YOU NEED TO KNOW ABOUT THE USE OF ANTIPSYCHOTIC DRUGS
Nuplazid™ - Pimavanserin
Seema Jain1, Rebecca Andridge2, Jessica Hellings3
Strategies to Reduce Antibiotic Resistance and to Improve Infection Control Robin Oliver, M.D., CPE.
Antipsychotics academic detailing
Antipsychotic Medication Reduction in Long Term Care
Management of Agitation in Dementia
Behavioural Symptoms of Dementia
The AHRQ Safety Program for Improving Antibiotic Use
The mehealth Portal and CQN ADHD Measurement
Antipsychotic Agents and Their Use in Schizophrenia
The Parkinson's Disease Psychosis Journal Club
Presentation transcript:

1 Just The Facts Ma’am Dementia Care & Anti-Psychotics Just The Facts Ma’am December 17, 2012 Ronald A. Savrin, MD, MBA, FACS Medical Director, Ohio KePRO

2 THE MEASURE  Numerator Long-stay residents who received antipsychotics  Denominator All long-stay residents except those with exclusions.  Exclusions –Schizophrenia –Tourette’s Syndrome (current or prior assessment) –Huntington’s Disease

3 THE BOX OEI

4 “Of a total of seventeen placebo controlled trials performed with olanzapine (Zyprexa),aripiprazole (Abilify), risperidone ( Risperdal), or quetiapine (Seroquel) in elderly demented patients with behavioral disorders, fifteen showed numerical increases in mortality in the drug-treated group compared to the placebo- treated patients.” “These studies enrolled a total of 5106 patients, and several analyses have demonstrated an approximately fold increase in mortality in these studies. Examination of the specific causes of these deaths revealed that most were either due to heart related events (e.g., heart failure, sudden death) or infections (mostly pneumonia).” FDA 4/11/2005 (emphasis added) The EVIDENCE

5 Medicare NH residents - 14% atypical antipsychotic  83% were for OFF-LABEL Use (no psychosis)  88% Black Box warning applied (dementia)  51% of claims were erroneous (no accepted indication)  22% Not in accordance with CMS standards –Excessive Dose – 10.4% –Excessive Duration – 9.4% –Without Indications– 8.0% –Inadequate Monitoring– 7.7% –Adverse Consequences– 4.7%(18.2% multiple) THE FUSS – OIG May 2011 OEI May /1/07 – 6/30/07

6  Diagnosis  Used On-Label for Specific Dx  Diagnosis  Used Off- Label for Specific Dx –Evidence DOES Support Drug for Diagnosis  Diagnosis  Used Off- Label for Specific Dx –Evidence DOES NOT Support Drug for Diagnosis  No Specific Diagnosis - ?? The Issue Antipsychotics Used - FOUR Possibilities

7 AripiprazoleOlanzapineQuetiapineRisperidone Standardized Mean Difference (95% CI).20 ( ).12 ( ).11 ( ).19 ( ) The Evidence Meta-analysis 2011 JAMA. 2011;306(12): Psychosis, Agitation, Global Behavioral Symptoms in Dementia BENEFITS Pooled Analysis: Neuropsychiatric Inventory (NPI) Score – 35% improvement Compared to Baseline (30%) 3.41 points above placebo (4.0)

8 AripiprazoleOlanzapineQuetiapineRisperidone Cardiovasc 1.20 (0.58 – 2.55) 2.3 (1.08 – 5.61) 1.10 (0.53 – 2.30) 2.10 ( ) CVA 0.70 ( ) 1.50 (0.33 – 7.44) 0.70 (0.10 – 3.08) 3.12 (1.32 – 8.21) Extrapyramidal 1.30 (0.68 – 2.57) (3.50 – ) 1.20 ( ) 3.00 (1.96 – 4.70) The Evidence Meta-analysis 2011 JAMA. 2011;306(12): OR (95% CI) Psychosis, Agitation, Global Behavioral Symptoms in Dementia RISKS

9 AripiprazoleOlanzapineQuetiapineRisperidone DementiaMod-HighLow Mod-High Dementia Psychosis LowMixed Mod-High Dementia Agitation LowMod-HighMixedMod-High The Evidence AHRQ – Sept

10  Diagnosis  FDA Approved On-Label Use  Diagnosis  Off- Label Use for Specific Dx –Evidence DOES Support Drug for Diagnosis  Diagnosis  Off- Label Use for Specific Dx –Evidence DOES NOT Support Drug for Diagnosis  No Specific Diagnosis The Issue

11  Diagnosis  FDA Approved On-Label Use  Diagnosis  Off- Label Use for Specific Dx –Evidence DOES Support Drug for Diagnosis  Diagnosis  Off- Label Use for Specific Dx –Evidence DOES NOT Support Drug for Diagnosis  No Specific Diagnosis The Issue

12  “While off label prescribing in this context does not always constitute inappropriate prescribing, use of antipsychotic drugs do have significant health risks in this population”  “reduce the unnecessary use of antipsychotic agents by refocusing the interdisciplinary team on a better understanding of the root cause of dementia related behaviors” American Medical Directors Association Letter – June 18, 2012

13  Use only if antipsychotic drug therapy is necessary to treat a specific condition as diagnosed and documented in Medical Record  Unless Clinically contraindicated: –Institute Gradual Dose Reductions –Provide Behavioral Interventions Guidelines

14 Reducing the Use of Antipsychotic Medications: First Steps on the Quality Improvement Journey December 17, 2012 Leasa Novak, LPN, BA